newsfilter
← Latest News
GlobeNewswire·

Trevena Reports Third Quarter 2022 Results and Provides Business Update

OLINVYK commercialization progresses with Vizient contract and receipt of CMS outpatient pass-through reimbursement Positive Phase 1 topline results for TRV045, a novel S1P receptor modulator; no serious adverse events